Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a ...

Hi, it’s Tom Maloney in New York and Benjamin Stupples in London, looking at the wealth of Wall Street’s latest rock stars.

In a politically charged business climate, the global banking giant joins peers in ending many diversity, equity, and ...

The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...

(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...

Asset Management One Co. Ltd. raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.4% during ...

New York State Teachers Retirement System lowered its stake in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 0.2% ...

Kenya BioVax Institute, a state agency, is offering lucrative job opportunities, with salaries exceeding KSh 148,000 per ...

The top US merger banker last year was a woman. Meet her and 19 other dealmakers who dominated the M&A rebound, from Goldman ...